Liguzinediol potentiates the metabolic remodeling by activating the AMPK/SIRT3 pathway and represses Caspase-3/GSDME-mediated pyroptosis to ameliorate cardiotoxicity

• Main Authors: Weijie Zhu (Author), Naqi Lian (Author), Jia Wang (Author), Fengming Zhao (Author), Bowen Liu (Author), Jiaxing Sheng (Author), Chenyan Zhang (Author), Xuan Zhou (Author), Wenbai Gao (Author), Chen Xie (Author), Haoyu Gu (Author), Yuxin Zhang (Author), Mianli Bian (Author), Miao Jiang (Author), Yu Li (Author)
• Format: Book
• Published: BMC, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Liguzinediol (Lig) has emerged as a promising candidate for mitigating Doxorubicin (DOX)-induced cardiotoxicity, a significant limitation in the clinical application of this widely used antineoplastic drug known for its efficacy. This study aimed to explore the effects and potent...